Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Roseberry T et al
Dual-agonist tirzepatide (GIP/GLP-1) has adult Phase 3 data across SURMOUNT-1 through SURMOUNT-4 but no published adolescent results [8]
In 2024, results from the extended SURMOUNT-1 program showed that pooled tirzepatide doses reduced the risk of progression to type 2 diabetes by 94 percent in adults with prediabetes and obesity or overweight over 176 weeks, and nearly 99 percent of treated participants remained diabetes-free at that time point
Zepbound injections shouldnt hurt
GLP-1 receptor agonists are effective weight loss medications that work by mimicking a hormone your body naturally produces
Structure 25 , 506513 (2017)
US$ 29.82
US$ 26.43
US$ 24.10
US$ 24.75
